<DOC>
	<DOCNO>NCT00176930</DOCNO>
	<brief_summary>The purpose study develop standard care treatment use allogeneic stem cell patient cancer blood . The protocol revise reflect study consider `` treatment guideline '' , rather research study .</brief_summary>
	<brief_title>Stem Cell Transplant Hematological Malignancy</brief_title>
	<detailed_description>Preparative regimen use total body irradiation ( TBI ) cyclophosphamide : 1. day -6 -5 : cyclophosphamide give , 2. day -4 , -3 , -2 , -1 : TBI give , 3. day 0 : stem cell bone marrow infuse . Alternate preparative therapy patient able receive TBI The chemotherapy ( cyclophosphamide busulfan ) give intent destroy bone marrow , eliminate cancerous prepare transplant donor 's blood stem cell suppress immune system . l. Ten day transplant ( Day 10 ) , subject admit bone marrow transplant unit place isolation reduce exposure infection . Isolation continue adequate number cell present blood fight infection . 2 . On day -9 , -8 , -7 , -6 busulfan give . 3 . On day -5 , -4 , -3 , -2 cyclophosphamide give . 4 . On day -1 therapy give ( day rest ) . 5 . On day 0 donor stem cell give intravenously . Additional cell may give day +1 2 need . Transplant : Subjects admit bone marrow transplant unit put isolation reduce exposure infectious agent . During time , receive preparative treatment outline . Once receive preparative regimen , stem cell obtain donor give intravenously . The new stem cell replace bone marrow damage treatment cancer . Isolation continue adequate number cell present blood fight infection . Subjects transfer bone marrow transplant unit discharge hospital medically ready . Subjects expect return follow-up bone marrow transplant clinic specific date determine physician .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Donor &lt; 75 year age good health . Recipients &lt; = 55 year , normal organ function ( exclude bone marrow ) Karnofsky activity assessment &gt; = 90 % . Recipients related unrelated donor match HLA A , B , DRB1 locus , mismatch relate unrelated ( &lt; 35 year old ) single HLA A , B , DRB1 locus . Recipients eligible one follow disease category Chronic myelogenous leukemia accelerate phase post blast crisis second great chronic phase ; chronic phase intolerant resistant tyrosine kinase inhibitor . Acute myelocytic leukemia first great remission , first , second third relapse . Acute lymphocytic leukemia 2nd great bone marrow remission . High risk child transplant first remission meet criterion Myelodysplastic syndrome . Myeloproliferative Diseases ( i.e . myelofibrosis , chronic myelomonocytic leukemia ( CMML ) ) Juvenile myelomonocytic leukemia Chronic lymphocytic leukemia Advanced nonHodgkin 's ( NHL ) . Advanced Hodgkin 's disease beyond PR2 ( &gt; CR3 , &gt; PR3 ) . Multiple Myeloma initial therapy . Donors recipient sign informed consent Exclusion Criteria donor recipients meet follow test criterion . require donor : antiHIV , Hepatitis B , surface antigen , antiHCV , CMV , HSV , EBV serology , prepriming . CBC , platelet count day apheresis , day 0 ( 1 2 need ) require recipient : antiHIV , Hepatitis B , surface antigen , antiHCV , CMV , HSV , EBV serology , pretransplant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>stem cell transplant</keyword>
	<keyword>chronic leukemia</keyword>
	<keyword>acute leukemia</keyword>
	<keyword>irradiation</keyword>
	<keyword>chemotherapy</keyword>
</DOC>